KARAN SHETH: Open Payments
NPI 1790404960 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,027 in 56 payments from 17 companies in 2025. Trend: 2023 $336 · 2024 $1,570 · 2025 $1,027
Food & beverage: $1,027
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $203 |
| GlaxoSmithKline, LLC. | 10 | $182 |
| Novo Nordisk Inc | 7 | $176 |
| ABBVIE INC. | 10 | $160 |
| Novartis Pharmaceuticals Corporation | 2 | $36 |
| Exact Sciences Corporation | 2 | $36 |
| Lilly USA, LLC | 2 | $28 |
| Abbott Laboratories | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
Products named: TRELEGY ELLIPTA, Wegovy, AIRSUPRA, VRAYLAR, UBRELVY, FARXIGA, QULIPTA, LEQVIO.
Industry payments across SC — which companies pay providers there.
